Lupin to expand Vadodara facility.

Mumbai-based pharma player Lupin Ltd., is all set to expand its Vadodara facility to make bulk drugs for cardiac, anti-infectives, anti-tuberculosis, neurology and other segments. The estimated project cost is around Rs. 270 crore.

The Dabhasa plant of Lupin near Vadodara is one of the leading bulk drug manufacturing sites for the company. 'The Dabhasa plant is one of our major active pharmaceutical ingredient manufacturing sites which also exports. It is a US Food and Drug Administration (USFDA) approved facility,' informed a senior company official. Meanwhile, the company is planning to expand the unit to add more bulk drugs belonging to the categories of anti-cholesterol, cardiac, neuropathic, respiratory, anti-infectives among others. The company is a leading global manufacturer of anti-tuberculosis bulk drugs like Ethambutol Hydrochloride and Rifampicin.

BS